Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Stock Short Interest Report for October

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 8,701 shares, a drop of 36.0% from the September 30th total of 13,598 shares. Based on an average daily volume of 35,468 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

Aspire Biopharma Trading Down 10.0%

Shares of NASDAQ:ASBP opened at $7.30 on Tuesday. Aspire Biopharma has a 12-month low of $3.31 and a 12-month high of $468.00. The stock’s 50-day moving average price is $8.54 and its 200-day moving average price is $17.50. The stock has a market capitalization of $10.24 million, a P/E ratio of -0.10 and a beta of 0.17.

About Aspire Biopharma

Aspire Biopharma, Inc is a clinical-stage biopharmaceutical company developing orally administered therapies using a proprietary fast-dissolving tablet and sublingual delivery platform. The company’s technology is designed to deliver active ingredients through the tissues beneath the tongue, potentially allowing rapid absorption while reducing reliance on the gastrointestinal tract and first-pass metabolism.

Aspire’s lead development program has focused on an orally dissolvable epinephrine product intended for the emergency treatment of severe allergic reactions, including anaphylaxis.